Filing Flows › Myriad Genetics (MYGN) › Guidance history
Myriad Genetics (MYGN) guidance history: what it guided and what it reported
Myriad Genetics gave guidance in 3 earnings releases on file since May 5, 2026. Its releases raised guidance twice and lowered it once.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $860M–$880M (May 5, 2026) → lowered $770M–$790M (Jul 30, 2026) → raised $780M–$790M (Nov 4, 2026) | — | to be reported | — |
EBITDA
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $37.0M–$49.0M (May 5, 2026) | — | to be reported | — |
The latest quarter
Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%, net loss $43.9M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
Questions
Does Myriad Genetics beat its guidance?
Myriad Genetics gave guidance in 3 earnings releases on file since May 5, 2026. Its releases raised guidance twice and lowered it once.
How often does Myriad Genetics raise guidance?
Its earnings releases raised guidance twice and lowered it once since May 5, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.